Your antibody program doesn’t fail because you picked the “wrong platform” as often as it fails because you picked the wrong partner. We get specific about how to choose a preclinical CRO for antibody discovery by starting with the one thing that should drive every decision: the target clinical profile. If the CRO can’t translate your clinical goals into a practical, testable preclinical plan, you’re not buying confidence, you’re buying activity.

We talk about why outsourcing is so common across biotech and pharma, from capital efficiency to speed, and why a disease-agnostic contract research organization can be an advantage when you need battle-tested execution. Then we dig into what “fully integrated” really means in biologics development: not just finding antibody sequences, but carrying knowledge into functional assays, pharmacology, stability, developability, and the steps that support IND-enabling work.

We also cover the biggest traps buyers fall into when comparing CRO quotes. A low price can hide missing deliverables, thin characterization, or a handoff that leaves you hunting for the next vendor. You’ll hear the exact questions we think you should ask before you sign: what you get at the end of the first round, what minimum product is delivered if the campaign underperforms, who runs your program, and whether the CRO can clearly explain the pros and cons of different antibody discovery approaches for your target. If you find this useful, subscribe, share it with a teammate, and leave a review with the one CRO question you wish you had asked sooner.

mosaicbio.com